Home › Research › Long-term cohort studies
Subjective Cognitive Decline Plus and Longitudinal Assessment and Risk for Cognitive Impairment
Kang M, Li C, Mahajan A, Spat-Lemus J, Durape S, Chen J, Gurnani AS, Devine S et al.. JAMA psychiatry, 2024-10-01
Topic: Risk, prevention and care in population studies
Importance Subjective cognitive decline (SCD) is recognized to be in the Alzheimer disease (AD) cognitive continuum. The SCD Initiative International Working Group recently proposed SCD-plus (SCD+) features that increase risk for future objective cognitive decline but that have not been assessed in a large community-based setting. Objective To assess SCD risk for mild cognitive impairment (MCI), AD, and all-cause dementia, using SCD+ criteria among cognitively normal adults.
Key findings
- The SCD Initiative International Working Group recently proposed SCD-plus (SCD+) features that increase risk for future objective cognitive decline but that have not been assessed in a large community-based setting.
- Objective To assess SCD risk for mild cognitive impairment (MCI), AD, and all-cause dementia, using SCD+ criteria among cognitively normal adults.
- Design, setting, and participants The Framingham Heart Study, a community-based prospective cohort study, assessed SCD between 2005 and 2019, with up to 12 years of follow-up.
- Participants 60 years and older with normal cognition at analytic baseline were included.
Why it matters
This cohort study assessed whether specific features of subjective cognitive decline predict future mild cognitive impairment, Alzheimer's disease, and all-cause dementia. It is about identifying risk, not about treating, curing, or preventing the disease.
Study details
- Study designcohort study
- Participants3,585
- Effect size55.1%; 44.5%; 21.5%
- Evidence strengthModerate
How this study scored 68/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA psychiatry) |
| Journal's citation record | 3 / 4 | JAMA Psychiatry: journal h-index 256 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 3,585 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 52 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 13.0 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 4 / 6 | Cited 14.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 3 / 4 | Cited 52 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Jesse Mez: h-index 59 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Boston University: institution h-index 1,456 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38959008) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 68 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamapsychiatry.2024.1678
- PubMed: 38959008
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Kang, M., Li, C., Mahajan, A., Spat-Lemus, J., Durape, S., Chen, J., et al. (2024). Subjective Cognitive Decline Plus and Longitudinal Assessment and Risk for Cognitive Impairment. JAMA psychiatry. https://doi.org/10.1001/jamapsychiatry.2024.1678
Vancouver
Kang M, Li C, Mahajan A, Spat-Lemus J, Durape S, Chen J, et al. Subjective Cognitive Decline Plus and Longitudinal Assessment and Risk for Cognitive Impairment. JAMA psychiatry. 2024. doi:10.1001/jamapsychiatry.2024.1678. PMID: 38959008.
BibTeX
@article{kang2024-38959008,
author = {Kang, M. and Li, C. and Mahajan, A. and Spat-Lemus, J. and Durape, S. and Chen, J. and Gurnani, A. S. and Devine, S. and others},
title = {{Subjective Cognitive Decline Plus and Longitudinal Assessment and Risk for Cognitive Impairment}},
journal = {JAMA psychiatry},
year = {2024},
doi = {10.1001/jamapsychiatry.2024.1678},
pmid = {38959008},
url = {https://doi.org/10.1001/jamapsychiatry.2024.1678}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 21.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Long-term cohort studies
Also tagged “assessment”
840 studies in the library carry the topic tag “assessment”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.